Investment Thesis
Phathom demonstrates exceptional revenue growth of 216.9% YoY with robust 79.4% gross margins, indicating strong commercial traction in their pharmaceutical business. However, the company faces critical fundamental challenges: negative stockholders' equity of -$337.0M, persistent operating losses of -$15.5M, and negative operating cash flow of -$15.6M despite revenue growth, signaling the company has not achieved operating leverage. With estimated 10-12 quarters of cash runway at current burn rates, profitability inflection must materialize soon.
Strengths
- Exceptional revenue growth of 216.9% YoY demonstrates strong market adoption and commercialization success
- Outstanding gross margin of 79.4% indicates pricing power, product quality, and favorable pharmaceutical economics
- Solid liquidity position with $180.9M cash and current ratio of 2.21x provides near-term operational flexibility
Risks
- Negative stockholders' equity of -$337.0M indicates technical balance sheet insolvency with liabilities exceeding assets by $337M
- Persistent cash burn of -$15.7M free cash flow despite strong revenue growth shows lack of operating leverage and pathway to sustainability unclear
- Operating losses of -$15.5M and net losses of -$30.4M combined with negative interest coverage ratio of -0.4x indicate inability to service $163.7M debt from operations
Key Metrics to Watch
- Operating cash flow inflection point and timeline to positive cash generation
- Quarterly progress toward operating profitability and operating margin expansion
- Stockholders' equity recovery trajectory and balance sheet recapitalization
Financial Metrics
Revenue
58.3M
Net Income
-30.4M
EPS (Diluted)
$-0.37
Free Cash Flow
-15.7M
Total Assets
305.1M
Cash
180.9M
Profitability Ratios
Gross Margin
79.4%
Operating Margin
-26.5%
Net Margin
-52.1%
ROE
N/A
ROA
-10.0%
FCF Margin
-26.9%
Balance Sheet & Liquidity
Current Ratio
2.21x
Quick Ratio
2.16x
Debt/Equity
N/A
Debt/Assets
210.4%
Interest Coverage
-0.44x
Long-term Debt
163.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T18:37:24.142236 |
Data as of: 2026-03-31 |
Powered by Claude AI